Recombinant VEGFR2 (Ramucirumab Biosimilar) anticorps

N° du produit ABIN7795122

L’anticorps Souris Monoclonal anti-VEGFR2 (Ramucirumab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter VEGFR2 (Ramucirumab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant VEGFR2 (Ramucirumab Biosimilar) anticorps (ABIN7795122)

Antigène: VEGFR2 (Ramucirumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp VEGFR2 (Ramucirumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-VEGFR2 (Ramucirumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody

Attributs du produit: What is ramucirumab biosimilar research grade? Research grade Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab. Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis. Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human VEGFR2

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur VEGFR2 (Ramucirumab Biosimilar)

Antigène: VEGFR2 (Ramucirumab Biosimilar)

Autre désignation: Ramucirumab Biosimilar

Classe de substances: Biosimilar